This update is based on a press release statement from Invivyd, Inc. The company's stock has experienced significant volatility, with a 16.39% gain in the past week despite a 64.17% decline over six ...

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Live-attenuated respiratory syncytial virus (RSV) vaccines are highly immunogenic among HIV-exposed uninfected (HEU) pediatric patients, according to results of a study published in Open Forum ...

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food ...

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as sus ...

Invivyd's Pemgarda showed neutralizing activity against 75%+ of ... 1 sublineages at low residual titers, was uploaded to MedRxiv. Price Action: IVVD stock is down 5.5% at $0.4357 at last check ...

Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified ... VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue ...

nanoparticle vaccines maintain high neutralizing antibody titers against coronavirus variants with just an annual booster (based on animal studies). The key to the nanoparticle-based vaccine lies ...

Neutralization titers were calculated as the inverse of the maximum dilution that prevented CPE formation. Additionally, neutralizing antibody titers against SARS-CoV-2 in the serum of monkeys that ...